Advertisement

Vitiligo pp 51-56 | Cite as

Vitiligo Universalis

  • Prasad Kumarasinghe

Core Messages

  • Vitiligo universalis is the most uncommon form of vitiligo and is probably the extreme severity end of the spectrum of nonsegmental vitiligo.

  • Associated autoimmune phenomena seem more common; patients have to be followed up, as associated diseases may manifest months or years after being diagnosed vitiligo universalis.

  • Sun protection is important to avoid sunburns and other sequelae.

  • Depigmenting creams such as monobenzyl ether of hydroquinone or laser depigmentation may be used to depigment small areas of breakthrough pigmentation.

Keywords

Contact Dermatitis Allergic Contact Dermatitis Lichen Planus Alopecia Areata Vitiligo Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

I am grateful to Prof Roy Chan, Medical Director and Dr. Goh Boon Kee, Consultant Dermatologist, of the National Skin Centre Singapore (where I worked earlier) for providing some of the photographs.

References

  1. 1.
    Alkhateeb A, Fain PR, Thody A et al (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16:208–214PubMedCrossRefGoogle Scholar
  2. 2.
    Aydogan K, Turan OF, Onart S et al (2006) Audiological abnormalities in patients with vitiligo. Clin Exp Dermatol 31:110–113PubMedCrossRefGoogle Scholar
  3. 3.
    Boisseau-Garsaud AM, Vezon G et al (2000) High prevalence of vitiligo in lepromatous leprosy. Int J Dermatol 39:837–839PubMedCrossRefGoogle Scholar
  4. 4.
    Dogra S, Kumar B (2005) Repigmentation in vitiligo universalis: role of melanocyte density, disease duration and mel-anocyte reservoir. Dermatol Online J 11:30PubMedGoogle Scholar
  5. 5.
    Gopal KV, Rama Rao GR, Kumar YH et al (2007) Vitiligo: a part of systemic autoimmune process. Indian J Dermatol Venereol Leprol 73:162–165PubMedCrossRefGoogle Scholar
  6. 6.
    Hann SK, Nordlund JJ (eds) (2000) Clinical features of generalized vitiligo. In: Vitiligo. Blackwell, Oxford, pp 81–88Google Scholar
  7. 7.
    Husain I, Vijayan E, Ramaiah A et al (1982) Demonstration of tyrosinase in the vitiligo skin of human beings by a sensitive fluorometric method as well as by 14C(U) l tyrosine incorporation into melanin. J Invest Dermatol 78:243–252PubMedCrossRefGoogle Scholar
  8. 8.
    Kumarasinghe SPW (1995) An optimistic approach to management of vitiligo. Ceylon Med J 40:94–96PubMedGoogle Scholar
  9. 9.
    McGowan JW, Long JB, Johnston CA, Lynn A (2006) Disseminated vitiligo associated with AIDS. Cutis 77:169–173PubMedGoogle Scholar
  10. 10.
    Mattoo SK, Handa S, Kaur I et al (2002) Psychiatric morbidity in vitiligo: prevalence and correlates in India. J Eur Acad Dermatol Venereol 16:573–578PubMedCrossRefGoogle Scholar
  11. 11.
    Nath SK, Majumder PP, Nordlund JJ (1994) Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Gene 55:981–990Google Scholar
  12. 12.
    Naughton GK, Eisenger M, Bystryn JC (1983) Antibodies to normal human melanocytes in vitiligo. J Exp Med 158:246–251PubMedCrossRefGoogle Scholar
  13. 13.
    Njoo MD, Vadegel RM, Westerhof W (2000 Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q switched ruby laser. J Am Acad Dermatol 42:760–769PubMedCrossRefGoogle Scholar
  14. 14.
    Nordlund JJ, Ortonne JP, Le Poole C (2006) Genetic hypomelanosis: acquired depigmentation. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne JP (eds) The Pigmentary system, 2nd edn. Blackwell, Malden, pp 551–598CrossRefGoogle Scholar
  15. 15.
    Pan JY, Goh BK, Theng C, Kumarasinghe SPW (2007) Vitiligo as a reaction to topical treatment with diphency-prone. In: Second Meeting of the Asian Society for Pigment Cell Research, Singapore, July 2007 (abstract in Pigment Cell Res 20:247)Google Scholar
  16. 16.
    Rao J, Fitzpatrick RE (2004) Use of Q switched 755 nm Alexandrite laser to treat recalcitrant pigment after depig-mentation therapy for vitiligo. Dermatol Surg 30:1043–1045PubMedCrossRefGoogle Scholar
  17. 17.
    Saban J, Rodriguez Garcia JL, Gil J et al (1991) Porphyria cutanea tarda associated with autoimmune hypothyroidism, vitiligo and alopecia universalis. Neth J Med 39:350–352PubMedGoogle Scholar
  18. 18.
    Schallreuter KU, Behrens-Williams S, Khaliq TP et al (2003) Increased epidermal functioning wildtype p53 expression in vitiligo. Exp Dermatol 12:268–277PubMedCrossRefGoogle Scholar
  19. 19.
    Shah AS, Supapannachart N, Nordlund JJ (1993) Acquired hypomelanotic disorders. In: Levine N (ed) Pigmentation and pigmentary disorders. CRS, Boca Raton, pp 337–351Google Scholar
  20. 20.
    Song MS, Hann SK, Ahn PS et al (1994) Clinical study of vitiligo: comparative study of Type A and Type B vitiligo. Annals Dermatol 6:22–30Google Scholar
  21. 21.
    Spritz RA (2007) The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res. 20:271–278PubMedCrossRefGoogle Scholar
  22. 22.
    Tan WP, Goh BK, Tee SI, Kumarasinghe SPW (2007) Clinical profile of vitiligo in Singapore. In: Second Meeting of the Asian Society for Pigment Cell Research, Singapore, July 2007 (abstract in Pigment Cell Res 20:253)Google Scholar
  23. 23.
    Thiessen M, Westerhof W (1997) Laser treatment for further depigmentation in vitiligo. Int J Dermatol 36:386–388CrossRefGoogle Scholar
  24. 24.
    Tobin DJ, Swanson NN, Pittlekow MR et al (2000) Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 191:407–416PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Consultant Dermatologist, Department of DermatologyRoyal Perth HospitalmWestern AustraliaAustralia

Personalised recommendations